altretamine has been researched along with Recrudescence in 3 studies
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment." | 2.42 | Recurrent ovarian cancer: how important is it to treat to disease progression? ( Herzog, TJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herzog, TJ | 1 |
| Edelman, DZ | 1 |
| Anteby, SO | 1 |
| Peretz, T | 1 |
| Ozols, RF | 1 |
3 reviews available for altretamine and Recrudescence
| Article | Year |
|---|---|
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2004 |
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neopla | 1996 |
Ovarian cancer: new clinical approaches.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Recu | 1991 |